ATE325796T1 - Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente - Google Patents
Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamenteInfo
- Publication number
- ATE325796T1 ATE325796T1 AT02760555T AT02760555T ATE325796T1 AT E325796 T1 ATE325796 T1 AT E325796T1 AT 02760555 T AT02760555 T AT 02760555T AT 02760555 T AT02760555 T AT 02760555T AT E325796 T1 ATE325796 T1 AT E325796T1
- Authority
- AT
- Austria
- Prior art keywords
- linear
- branched
- alkyl
- aryl
- alkenyl
- Prior art date
Links
- 102000007471 Adenosine A2A receptor Human genes 0.000 title abstract 2
- 108010085277 Adenosine A2A receptor Proteins 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- UCJKLYSNBVUUDM-UHFFFAOYSA-N 2-(2h-triazol-4-yl)-7h-purine Chemical compound N=1C=C2NC=NC2=NC=1C1=CNN=N1 UCJKLYSNBVUUDM-UHFFFAOYSA-N 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000005915 C6-C14 aryl group Chemical group 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 101100294115 Caenorhabditis elegans nhr-4 gene Chemical group 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001RM000465A ITRM20010465A1 (it) | 2001-07-31 | 2001-07-31 | Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE325796T1 true ATE325796T1 (de) | 2006-06-15 |
Family
ID=11455703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02760555T ATE325796T1 (de) | 2001-07-31 | 2002-07-25 | Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7230102B2 (https=) |
| EP (1) | EP1412354B1 (https=) |
| JP (1) | JP4366186B2 (https=) |
| KR (1) | KR100884818B1 (https=) |
| CN (1) | CN1271070C (https=) |
| AT (1) | ATE325796T1 (https=) |
| AU (1) | AU2002326146B2 (https=) |
| BR (1) | BR0211550A (https=) |
| CA (1) | CA2451279C (https=) |
| DE (1) | DE60211343T2 (https=) |
| DK (1) | DK1412354T3 (https=) |
| ES (1) | ES2263810T3 (https=) |
| HU (1) | HU228985B1 (https=) |
| IT (1) | ITRM20010465A1 (https=) |
| MX (1) | MXPA04000886A (https=) |
| PL (1) | PL217269B1 (https=) |
| PT (1) | PT1412354E (https=) |
| WO (1) | WO2003011864A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1401837T3 (da) * | 2001-06-29 | 2005-11-07 | Cv Therapeutics Inc | Purinderivater som A2B-adenosinreceptorantagonister |
| ITRM20010465A1 (it) * | 2001-07-31 | 2003-01-31 | Sigma Tau Ind Farmaceuti | Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam |
| ES2279903T3 (es) * | 2001-12-18 | 2007-09-01 | Cv Therapeutics, Inc. | Antagonistas del receptor a2a de adenosina. |
| US8012964B2 (en) | 2004-03-26 | 2011-09-06 | Dainippon Sumitomo Pharma Co., Ltd. | 9-substituted 8-oxoadenine compound |
| US8063063B2 (en) * | 2006-03-23 | 2011-11-22 | Novartis Ag | Immunopotentiating compounds |
| US8138172B2 (en) | 2006-07-05 | 2012-03-20 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of TLR7 |
| TW200831105A (en) | 2006-12-14 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
| ES2457316T3 (es) | 2007-03-19 | 2014-04-25 | Astrazeneca Ab | Compuestos 8-oxo-adenina 9 sustituidos como moduladores del receptor similares a toll (TLR7) |
| ES2373616T3 (es) | 2007-03-19 | 2012-02-07 | Astrazeneca Ab | Compuestos de 8-oxo-adenina 9 sustituidos como moduladores del receptor de tipo toll (tlr7). |
| JPWO2008114819A1 (ja) | 2007-03-20 | 2010-07-08 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
| AR065784A1 (es) * | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
| KR101313804B1 (ko) | 2007-03-20 | 2013-10-01 | 쿠리스 인코퍼레이션 | Ｈｓｐ９０ 억제제로서의 융합된 아미노 피리딘 |
| HRP20120895T1 (hr) * | 2007-05-08 | 2012-11-30 | Astrazeneca Ab | Imidazokinolini sa imuno-modulacijskim svojstvima |
| PE20091156A1 (es) | 2007-12-17 | 2009-09-03 | Astrazeneca Ab | Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo |
| WO2009091032A1 (ja) | 2008-01-17 | 2009-07-23 | Dainippon Sumitomo Pharma Co., Ltd. | アデニン化合物の製造方法 |
| JPWO2009091031A1 (ja) * | 2008-01-17 | 2011-05-26 | 大日本住友製薬株式会社 | アデニン化合物の製造方法 |
| TWI473614B (zh) | 2008-05-29 | 2015-02-21 | Kyowa Hakko Kirin Co Ltd | Anti-analgesic inhibitors |
| CA2729128C (en) | 2008-07-03 | 2016-05-31 | Sirtris Pharmaceuticals, Inc. | Benzimidazoles and related analogs as sirtuin modulators |
| KR20110040856A (ko) * | 2008-07-23 | 2011-04-20 | 교와 핫꼬 기린 가부시키가이샤 | 편두통 치료제 |
| EP2408775B1 (en) * | 2009-03-20 | 2015-06-17 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Oxidated derivatives of triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments |
| US20120295863A1 (en) * | 2009-11-13 | 2012-11-22 | Yun-Lian Lin | Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases |
| JP2013512859A (ja) * | 2009-12-03 | 2013-04-18 | 大日本住友製薬株式会社 | トール様受容体（ｔｌｒ）を介して作用するイミダゾキノリン |
| JP5714602B2 (ja) * | 2010-11-24 | 2015-05-07 | ヤマサ醤油株式会社 | 新規な２−アルキニル−ｎ９−プロパギルアデニンおよびその医薬用途 |
| CN103370317B (zh) | 2010-12-16 | 2015-10-07 | 阿斯利康(瑞典)有限公司 | 可用于治疗的咪唑并[4,5-c]喹啉-1-基衍生物 |
| ES2627433T3 (es) | 2010-12-17 | 2017-07-28 | Sumitomo Dainippon Pharma Co., Ltd. | Derivados de purina |
| CN105189495A (zh) * | 2013-03-15 | 2015-12-23 | 先正达参股股份有限公司 | 新颖的杀微生物剂 |
| CN105622495A (zh) * | 2016-03-23 | 2016-06-01 | 叶芳 | 4-氯-3-硝基吡啶及其制备方法 |
| PL3280414T3 (pl) | 2016-04-15 | 2024-06-24 | Oxford University Innovation Limited | Modulatory receptora adenozyny w leczeniu schorzeń rytmu okołodobowego |
| WO2025080645A1 (en) * | 2023-10-10 | 2025-04-17 | Regranion, Llc | Methods and compositions for treating bullous pemphigoid |
| GB202319534D0 (en) * | 2023-12-19 | 2024-01-31 | Circadian Therapeutics Ltd | Dosage regimen |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR910700253A (ko) * | 1989-01-31 | 1991-03-14 | 로버트 제이, 바란 | N_6-치환-9-메틸아데닌: 신규한 부류의 아데노신 수용체 길항질 |
| US5670501A (en) | 1994-09-01 | 1997-09-23 | Discovery Therapeutics, Inc. | N-substituted 9-alkyladenines |
| AU1688599A (en) | 1998-01-05 | 1999-07-26 | Eisai Co. Ltd. | Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes |
| GB9915437D0 (en) * | 1999-07-01 | 1999-09-01 | Cerebrus Ltd | Chemical compounds III |
| DK1401837T3 (da) * | 2001-06-29 | 2005-11-07 | Cv Therapeutics Inc | Purinderivater som A2B-adenosinreceptorantagonister |
| ITRM20010465A1 (it) | 2001-07-31 | 2003-01-31 | Sigma Tau Ind Farmaceuti | Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam |
-
2001
- 2001-07-31 IT IT2001RM000465A patent/ITRM20010465A1/it unknown
-
2002
- 2002-07-25 CA CA2451279A patent/CA2451279C/en not_active Expired - Fee Related
- 2002-07-25 ES ES02760555T patent/ES2263810T3/es not_active Expired - Lifetime
- 2002-07-25 MX MXPA04000886A patent/MXPA04000886A/es active IP Right Grant
- 2002-07-25 AU AU2002326146A patent/AU2002326146B2/en not_active Ceased
- 2002-07-25 JP JP2003517056A patent/JP4366186B2/ja not_active Expired - Fee Related
- 2002-07-25 WO PCT/IT2002/000489 patent/WO2003011864A1/en not_active Ceased
- 2002-07-25 EP EP02760555A patent/EP1412354B1/en not_active Expired - Lifetime
- 2002-07-25 BR BR0211550-6A patent/BR0211550A/pt not_active IP Right Cessation
- 2002-07-25 CN CNB028138481A patent/CN1271070C/zh not_active Expired - Fee Related
- 2002-07-25 PL PL368409A patent/PL217269B1/pl unknown
- 2002-07-25 DK DK02760555T patent/DK1412354T3/da active
- 2002-07-25 DE DE60211343T patent/DE60211343T2/de not_active Expired - Lifetime
- 2002-07-25 US US10/484,491 patent/US7230102B2/en not_active Expired - Fee Related
- 2002-07-25 AT AT02760555T patent/ATE325796T1/de active
- 2002-07-25 KR KR1020047000173A patent/KR100884818B1/ko not_active Expired - Fee Related
- 2002-07-25 PT PT02760555T patent/PT1412354E/pt unknown
- 2002-07-25 HU HU0401987A patent/HU228985B1/hu not_active IP Right Cessation
-
2007
- 2007-05-04 US US11/797,566 patent/US7528252B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP4366186B2 (ja) | 2009-11-18 |
| EP1412354A1 (en) | 2004-04-28 |
| PL368409A1 (en) | 2005-03-21 |
| JP2005500355A (ja) | 2005-01-06 |
| PT1412354E (pt) | 2006-09-29 |
| US20040204428A1 (en) | 2004-10-14 |
| KR20040023641A (ko) | 2004-03-18 |
| ITRM20010465A1 (it) | 2003-01-31 |
| CA2451279A1 (en) | 2003-02-13 |
| MXPA04000886A (es) | 2004-06-03 |
| HK1068334A1 (en) | 2005-04-29 |
| PL217269B1 (pl) | 2014-06-30 |
| US7528252B2 (en) | 2009-05-05 |
| HU228985B1 (en) | 2013-07-29 |
| DE60211343D1 (de) | 2006-06-14 |
| DE60211343T2 (de) | 2007-05-10 |
| CN1525974A (zh) | 2004-09-01 |
| ITRM20010465A0 (it) | 2001-07-31 |
| DK1412354T3 (da) | 2006-09-18 |
| BR0211550A (pt) | 2004-07-13 |
| US7230102B2 (en) | 2007-06-12 |
| EP1412354B1 (en) | 2006-05-10 |
| HUP0401987A2 (hu) | 2005-01-28 |
| AU2002326146B2 (en) | 2008-05-01 |
| CN1271070C (zh) | 2006-08-23 |
| KR100884818B1 (ko) | 2009-02-20 |
| ES2263810T3 (es) | 2006-12-16 |
| HUP0401987A3 (en) | 2012-12-28 |
| CA2451279C (en) | 2011-05-10 |
| US20070249638A1 (en) | 2007-10-25 |
| WO2003011864A1 (en) | 2003-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE325796T1 (de) | Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente | |
| BRPI0606319A2 (pt) | compostos farmacêuticos | |
| AR004516A1 (es) | Derivados de pirimidina, su uso, procedimientos para prepararlos y medicamentos que los contienen | |
| BRPI0409938A (pt) | derivados de azetidinacarboxamida e seu uso em terapia | |
| ATE453639T1 (de) | Phenylsubstituierte pyrimidinverbindungen zur verwendung als kinasehemmer | |
| TW200716528A (en) | Cyclopropanecarboxamide derivatives | |
| MXPA05011710A (es) | Derivados de pirimidina con actividad de crf. | |
| DE60043349D1 (de) | Chinazolin-derivate und ihre verwendung als arzneimittel | |
| MY126862A (en) | Purine derivatives inhibitors of tyrosine protein kinase syk | |
| HUP0401047A2 (hu) | Triazolo[4,5-d]pirimidin-származékok, alkalmazásuk purinergikus receptor-antagonistákként és a vegyületet tartalmazó gyógyszerkészítmények | |
| CY1105233T1 (el) | Παραγωγα κατιοντος 1,2,4 - θειαδιαζολιου ως ρυθμιστες υποδοχεα μελανοκορτινης | |
| MXPA05010621A (es) | Pirimidinonas sustituidas. | |
| MXPA04001240A (es) | Analogos antitumorales. | |
| EA200400466A1 (ru) | Производные пиперазина с антагонистической активностью к рецептору ccr1 | |
| CY1107677T1 (el) | Παραγωγα της 1-[indol-3-yl)carbonyl]piperazine | |
| CY1116183T1 (el) | Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης | |
| ATE374190T1 (de) | Tetrahydrochinazolinderivate als cfr-antagonisten | |
| DE69924292D1 (de) | Pyrazol verbindungen und ihre verwendung | |
| CY1110145T1 (el) | Αλκυλο-υποκατεστημενες ινδολοκινοξαλινες | |
| BR0213026A (pt) | Compostos de imidazopiridina como reguladores do receptor 5-ht4 | |
| ATE505462T1 (de) | Neue biologischaktive molekü le | |
| ES2197003A1 (es) | Nuevos compuestos antagonistas de integrinas alfa. | |
| PT1022276E (pt) | Derivados de epoxissuccinamida | |
| ATE429421T1 (de) | Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten | |
| MXPA05010651A (es) | Compuestos de pirazol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1412354 Country of ref document: EP |